Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Quanxing Ni

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112126799. Sources: OpenAlex.

Their work

Papers
84 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
128
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 3 papers · 2014: 3 papers · 2015: 11 papers · 2016: 9 papers · 2017: 14 papers · 2018: 16 papers · 2019: 12 papers · 2020: 5 papers · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 50 of 84

  1. Glucose is a potential source of glutamate for glutamine-deprived pancreatic cancer cells with KRAS mutation Co-author DOI 10.3724/abbs.2026063↗
  2. Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics. Co-author DOI 10.1097/sla.0000000000006168↗
  3. Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Co-author DOI 10.1007/s12020-022-03196-4↗
  4. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.1007/s12672-023-00628-z↗
  5. Glutamine deprivation induces ferroptosis in pancreatic cancer cells. Co-author DOI 10.3724/abbs.2023029↗
  6. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Co-author DOI 10.1016/j.bbcan.2020.188409↗
  7. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-021-02147-z↗
  8. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.016↗
  9. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002998↗
  10. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy. Co-author DOI 10.1177/1073274820915947↗
  11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-020-00958-3↗
  12. Lewis antigen‑negative pancreatic cancer: An aggressive subgroup. Co-author DOI 10.3892/ijo.2020.4989↗
  13. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Co-author DOI 10.1002/cam4.1957↗
  14. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  15. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. Co-author DOI 10.1016/j.ejso.2019.01.018↗
  16. Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes. Co-author DOI 10.1097/mpa.0000000000001338↗
  17. Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002668↗
  18. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  19. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  20. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  21. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6941-4↗
  22. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.2147/cmar.s197911↗
  23. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Co-author DOI 10.2147/cmar.s211363↗
  24. Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.7150/jca.29898↗
  25. MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. Co-author DOI 10.1002/ijc.31654↗
  26. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Co-author DOI 10.1007/s00018-017-2678-7↗
  27. Guidelines for the diagnosis and treatment of pancreatic adenocarcinoma (2018 edition): A standardized procedure recommended in China. Co-author DOI 10.1016/j.hbpd.2018.07.004↗
  28. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2018.05.479↗
  29. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.08.003↗
  30. Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.surg.2017.12.009↗
  31. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  32. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  33. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Co-author DOI 10.1038/s41419-018-1244-z↗
  34. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001073↗
  35. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  36. Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6727-8↗
  37. Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining? Co-author DOI 10.2147/ott.s166405↗
  38. Zinc finger E-box-binding homeobox 1 mediates aerobic glycolysis via suppression of sirtuin 3 in pancreatic cancer. Co-author DOI 10.3748/wjg.v24.i43.4893↗
  39. The Significance of Liquid Biopsy in Pancreatic Cancer. Co-author DOI 10.7150/jca.24591↗
  40. Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes. Co-author PMID 29636993↗
  41. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Co-author DOI 10.1002/ijc.30650↗
  42. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  43. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
  44. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Co-author DOI 10.1038/emm.2017.255↗
  45. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000001741↗
  46. Aspirin Use and Reduced Risk of Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-16-0508↗
  47. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  48. Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5579-3↗
  49. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.2147/ott.s145708↗
  50. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗

Closest collaborators

The 25 strongest of 128 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 76 shared papers, 2012–2024 · strength 5.73
  2. Jin Xu · 49 shared papers, 2012–2020 · strength 3.13
  3. Guopei Luo · 32 shared papers, 2012–2026 · strength 2.91
  4. Chen Liu · 39 shared papers, 2012–2023 · strength 2.55
  5. Si Shi · 28 shared papers, 2014–2020 · strength 1.92
  6. Kaizhou Jin · 25 shared papers, 2015–2021 · strength 1.82
  7. Chen Liang · 22 shared papers, 2016–2020 · strength 1.56
  8. Yi Qin · 24 shared papers, 2014–2019 · strength 1.51
  9. Liang Liu · 26 shared papers, 2013–2019 · strength 1.44
  10. Shunrong Ji · 24 shared papers, 2012–2019 · strength 1.44
  11. Zhiwen Xiao · 13 shared papers, 2012–2026 · strength 1.42
  12. Dingkong Liang · 20 shared papers, 2015–2019 · strength 1.26
  13. Jiang Long · 23 shared papers, 2012–2018 · strength 1.18
  14. He Cheng · 14 shared papers, 2016–2021 · strength 1.18
  15. Qingcai Meng · 14 shared papers, 2017–2020 · strength 1.13
  16. Wenyan Xu · 20 shared papers, 2012–2019 · strength 1.12
  17. Huaxiang Xu · 11 shared papers, 2015–2023 · strength 0.86
  18. Yitao Gong · 8 shared papers, 2019–2021 · strength 0.85
  19. Zhiyao Fan · 8 shared papers, 2018–2021 · strength 0.80
  20. Meng Guo · 13 shared papers, 2015–2018 · strength 0.78
  21. Jie Hua · 8 shared papers, 2018–2020 · strength 0.74
  22. Qiangsheng Hu · 11 shared papers, 2016–2019 · strength 0.74
  23. Chuntao Wu · 11 shared papers, 2014–2019 · strength 0.70
  24. Yunzhen Qian · 6 shared papers, 2020–2021 · strength 0.67
  25. Jinfeng Xiang · 11 shared papers, 2015–2018 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.